Correlation Between AptaBio Therapeutics and Kuk Young

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both AptaBio Therapeutics and Kuk Young at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining AptaBio Therapeutics and Kuk Young into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between AptaBio Therapeutics and Kuk Young GM, you can compare the effects of market volatilities on AptaBio Therapeutics and Kuk Young and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in AptaBio Therapeutics with a short position of Kuk Young. Check out your portfolio center. Please also check ongoing floating volatility patterns of AptaBio Therapeutics and Kuk Young.

Diversification Opportunities for AptaBio Therapeutics and Kuk Young

-0.45
  Correlation Coefficient

Very good diversification

The 3 months correlation between AptaBio and Kuk is -0.45. Overlapping area represents the amount of risk that can be diversified away by holding AptaBio Therapeutics and Kuk Young GM in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Kuk Young GM and AptaBio Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on AptaBio Therapeutics are associated (or correlated) with Kuk Young. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Kuk Young GM has no effect on the direction of AptaBio Therapeutics i.e., AptaBio Therapeutics and Kuk Young go up and down completely randomly.

Pair Corralation between AptaBio Therapeutics and Kuk Young

Assuming the 90 days trading horizon AptaBio Therapeutics is expected to under-perform the Kuk Young. But the stock apears to be less risky and, when comparing its historical volatility, AptaBio Therapeutics is 3.17 times less risky than Kuk Young. The stock trades about -0.29 of its potential returns per unit of risk. The Kuk Young GM is currently generating about 0.02 of returns per unit of risk over similar time horizon. If you would invest  204,500  in Kuk Young GM on September 3, 2024 and sell it today you would lose (9,800) from holding Kuk Young GM or give up 4.79% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

AptaBio Therapeutics  vs.  Kuk Young GM

 Performance 
       Timeline  
AptaBio Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days AptaBio Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.
Kuk Young GM 

Risk-Adjusted Performance

5 of 100

 
Weak
 
Strong
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Kuk Young GM are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, Kuk Young sustained solid returns over the last few months and may actually be approaching a breakup point.

AptaBio Therapeutics and Kuk Young Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with AptaBio Therapeutics and Kuk Young

The main advantage of trading using opposite AptaBio Therapeutics and Kuk Young positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if AptaBio Therapeutics position performs unexpectedly, Kuk Young can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Kuk Young will offset losses from the drop in Kuk Young's long position.
The idea behind AptaBio Therapeutics and Kuk Young GM pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.

Other Complementary Tools

Equity Valuation
Check real value of public entities based on technical and fundamental data
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated